Home
AI Agent
Annotations
Files

Pricing and plans
Get the full experience
We save the real magic for signed-in users.

Home Stock Screener Document Search Charting Watchlists Recent Filings

Tenax Therapeutics, Inc.(TENX US)

$1.62+0.010.62%Ext:$1.65+0.031.85%(Market Closed · 00:55:39 UTC)

Doc Search Profile Entity StructureFinancials Charting Short Interest Employees

Overview

Profile Entity Structure

Documents

Categorized Chronological By Owner

Financials & Metrics

Financials Charting Short Interest Employees

Home
AI Agent
Annotations
Files

Pricing and plans
Get the full experience
We save the real magic for signed-in users.

Home Stock Screener Document Search Charting Watchlists Recent Filings

Tenax Therapeutics, Inc.(TENX US)

$1.62+0.010.62%Ext:$1.65+0.031.85%(Market Closed · 00:55:39 UTC)

Doc Search Profile Entity StructureFinancials Charting Short Interest Employees

Overview

Profile Entity Structure

Documents

Categorized Chronological By Owner

Financials & Metrics

Financials Charting Short Interest Employees

TENX US

TENX US

Chronological SEC Filings

Chronological SEC Filings

Non-Ownership Filings(619)

10-QQ3ended 30 Sept 20265 Nov
8-KTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update5 Nov
8-KOther Events8 Oct
8-KRegulation FD Disclosure9 Sep
8-KTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial ofTNX-103in Patients withPH-HFpEF10 Aug
10-QQ2ended 30 Jun 202631 Jul
8-KTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update31 Jul
8-KTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 20262 Jul
8-KEntry into a Material Definitive Agreement30 Jun
8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers29 Jun
8-KSubmission of Matters to a Vote of Security Holders4 Jun
S-8Registration statement (employee benefit plan)12 May
10-QQ1ended 31 Mar 202612 May
8-KTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update12 May
ARSAnnual report to security holders22 Apr
DEFA14ADefinitive additional materials22 Apr
DEF 14ADefinitive proxy statement22 Apr
8-KTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer22 Apr
EFFECTNotice of effectiveness2 Apr
CORRESPFiling review correspondence31 Mar

Ownership Filings(343)

SC 13G/ATENAX THERAPEUTICS, INC.12 Nov
SC 13G/ATENAX THERAPEUTICS, INC.27 Oct
Form 4ADAR1 Capital Management, LLC21 Oct
SC 13G/ATENAX THERAPEUTICS, INC.15 Oct
SC 13G/ATENAX THERAPEUTICS, INC.13 Oct
SC 13G/ATENAX THERAPEUTICS, INC.9 Oct
Form 4Doogan Declan17 Sep
Form 4Giordano Christopher Thomas15 Sep
Form 4STAAB THOMAS R II15 Sep
SC 13G/ATENAX THERAPEUTICS, INC.11 Sep
Form 4Schneeberger Daniel8 Sep
SC 13GTENAX THERAPEUTICS, INC.8 Sep
SC 13G/ATENAX THERAPEUTICS, INC.8 Sep
Form 4Schneeberger Daniel2 Sep
SC 13GTENAX THERAPEUTICS, INC.27 Aug
SC 13GTENAX THERAPEUTICS, INC.27 Aug
Form 4ADAR1 Capital Management, LLC24 Aug
Form 3ADAR1 Capital Management, LLC24 Aug
SC 13GTENAX THERAPEUTICS, INC.18 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug

Non-Ownership Filings(619)

10-QQ3ended 30 Sept 20265 Nov
8-KTenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update5 Nov
8-KOther Events8 Oct
8-KRegulation FD Disclosure9 Sep
8-KTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial ofTNX-103in Patients withPH-HFpEF10 Aug
10-QQ2ended 30 Jun 202631 Jul
8-KTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update31 Jul
8-KTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 20262 Jul
8-KEntry into a Material Definitive Agreement30 Jun
8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers29 Jun
8-KSubmission of Matters to a Vote of Security Holders4 Jun
S-8Registration statement (employee benefit plan)12 May
10-QQ1ended 31 Mar 202612 May
8-KTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update12 May
ARSAnnual report to security holders22 Apr
DEFA14ADefinitive additional materials22 Apr
DEF 14ADefinitive proxy statement22 Apr
8-KTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer22 Apr
EFFECTNotice of effectiveness2 Apr
CORRESPFiling review correspondence31 Mar

Ownership Filings(343)

SC 13G/ATENAX THERAPEUTICS, INC.12 Nov
SC 13G/ATENAX THERAPEUTICS, INC.27 Oct
Form 4ADAR1 Capital Management, LLC21 Oct
SC 13G/ATENAX THERAPEUTICS, INC.15 Oct
SC 13G/ATENAX THERAPEUTICS, INC.13 Oct
SC 13G/ATENAX THERAPEUTICS, INC.9 Oct
Form 4Doogan Declan17 Sep
Form 4Giordano Christopher Thomas15 Sep
Form 4STAAB THOMAS R II15 Sep
SC 13G/ATENAX THERAPEUTICS, INC.11 Sep
Form 4Schneeberger Daniel8 Sep
SC 13GTENAX THERAPEUTICS, INC.8 Sep
SC 13G/ATENAX THERAPEUTICS, INC.8 Sep
Form 4Schneeberger Daniel2 Sep
SC 13GTENAX THERAPEUTICS, INC.27 Aug
SC 13GTENAX THERAPEUTICS, INC.27 Aug
Form 4ADAR1 Capital Management, LLC24 Aug
Form 3ADAR1 Capital Management, LLC24 Aug
SC 13GTENAX THERAPEUTICS, INC.18 Aug
SC 13G/ATENAX THERAPEUTICS, INC.14 Aug